Trial Profile
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2014
Price :
$35
*
At a glance
- Drugs STX 107 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Seaside Therapeutics
- 28 Nov 2014 New trial record